Repro-Med Systems Inc. reported increases in both domestic and international sales for the fiscal year ended February 29, 2012. This year the company continued the growth trend of recent years, with $6,390,534 in revenue which represents an increase of 29.9% over the previous fiscal year. Its FREEDOM60(R) product line realized a 31.9% increase in sales. Its net operating profit was $1,289,158 and its net income for the year was $815,893.

On October 20, 2011, the Board of Directors of Repro-Med Systems Inc. approved the engagement of Radin, Glass & Co., LLP as the company's independent registered public accounting firm for the year ending February 29, 2012. RGC's engagement as the company's independent registered public accounting firm commenced on October 20, 2011. On the same day, the Board of Directors dismissed McGrail, Merkel, Quinn & Associates as the company's independent registered public accounting firm.

Repro-Med Systems Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo(TM) RMS Subcutaneous Needle Sets. The needle sets are intended for the delivery of medication to subcutaneous tissue. The needle sets have previously been approved and available for use by patients in Canada and Europe. Repro-Med Systems Inc. utilizes the name RMS Medical Products. The needle sets are an ideal companion for RMS Medical Products' FREEDOM60(R) Syringe Infusion System, which has enhanced the lifestyle of numerous patients requiring regular drug infusions due to its portability and ease of use. FREEDOM60(R) enjoys widespread use by ambulatory patients at home as well as those in healthcare facilities. The RMS Subcutaneous Needle Sets use custom designed, approximately 26-gauge needles, which have a smaller outside diameter than commonly used 24-gauge needles. This translates into less 'ouch' when the needles are inserted, and greater comfort throughout lengthy infusions. The sets have superior fluidics resulting in faster flow rates. When used in multi-needle sets, as typically is the case for subcutaneous immune globulin infusions, the RMS Subcutaneous Needle Sets distribute equal volumes of drug to all needles. The sets are available in single, double, triple, and quad configurations. RMS produces a low residual 'Y' connector, which allows up to eight needles to be used for a single infusion. Needles lengths currently available are 6mm, 9mm, and 12mm.